Skip to main content
Top
Published in: Head & Neck Oncology 1/2012

Open Access 01-12-2012 | Research

Effect of human beta-defensin-3 on head and neck cancer cell migration using micro-fabricated cell islands

Authors: Kevin Wang, Joanne H Wang, Harihara Baskaran, Russell Wang, Rick Jurevic

Published in: Head & Neck Oncology | Issue 1/2012

Login to get access

Abstract

Background

To examine the effect of the natural antimicrobial peptide human β-defensin-3 (hBD-3), on the migration of a head and neck cancer cell line in vitro using microfabrication and soft-lithographic techniques.

Methods

TR146 cancer cells were seeded in Petri dishes with microfabricated wells for cell migration assays. Total 54 cell islands were used of various shape and size and experimental media type. Cell migration assays were analyzed in six group media: Dulbecco’s modified medium (DMEM); DMEM with vascular endothelial growth factor (VEGF); Conditioned media of human embryonic kidney cells (HEK 239) expressing hBD-3 via transfected cloned pcDNA3 as CM/hBD-3; CM/hBD-3 + VEGF; conditioned medium from non-transfected HEK 239 (not expressing hBD-3) as control (CM); and the last group was CM + VEGF. Cell islands were circular or square and varied in size (0.25 mm2, 0.125 mm2, and 0.0625 mm2). Cell islands were imaged at t = 0 h, 3 h, 6 h, and 24 h.

Results

The results show cancer cell islands that originally were smaller had higher migration indices. There was no difference of MIs between circular and square cell islands. MIs at the end point were significantly different among the groups except between CM and CM-hBD-3+ VEGF.

Conclusions

VEGF enhanced cancer cell migration. The combination of DMEM and VEGF showed a synergistic effect on this phenomenon of cancer cell migration. Conditioned medium with hBD-3 suppressed cancer cell migration. hBD-3 suppressed VEGF enhancement of TR146 cancer cell migration.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cancer Facts and Figures 2011. 2011, Atlanta: American Cancer Society. October Cancer Facts and Figures 2011. 2011, Atlanta: American Cancer Society. October
2.
go back to reference Brodt P: Cell adhesion and invasion in cancer metastasis. 1996, New York: Chapman & Hal Brodt P: Cell adhesion and invasion in cancer metastasis. 1996, New York: Chapman & Hal
3.
go back to reference Jones D, Nakashima T, Sanchez O, et al: Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006, 440: 692-696. 10.1038/nature04524.CrossRefPubMed Jones D, Nakashima T, Sanchez O, et al: Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006, 440: 692-696. 10.1038/nature04524.CrossRefPubMed
4.
5.
go back to reference Diamond G, Kimball J, Krisanaprakornki S, Dale B: Detection of β-defensins secreted by human oral epithelial cells. J Immune Meth. 2001, 256: 65-76. 10.1016/S0022-1759(01)00442-2.CrossRef Diamond G, Kimball J, Krisanaprakornki S, Dale B: Detection of β-defensins secreted by human oral epithelial cells. J Immune Meth. 2001, 256: 65-76. 10.1016/S0022-1759(01)00442-2.CrossRef
6.
go back to reference Donald CD, Sun CQ, Lim SD, et al: Cancer specific loss of beta-defensin 1 in renal and prostatic carcinomas. Lab Invest. 2003, 83: 501-505. 10.1097/01.LAB.0000063929.61760.F6.CrossRefPubMed Donald CD, Sun CQ, Lim SD, et al: Cancer specific loss of beta-defensin 1 in renal and prostatic carcinomas. Lab Invest. 2003, 83: 501-505. 10.1097/01.LAB.0000063929.61760.F6.CrossRefPubMed
7.
go back to reference Young AN, Salles PG, Lim SD, et al: Beta defensin-1, parvalbumin, and vimentin: a panel of diagnostic immunohistochemical markers for renal tumors derived from gene expression profiling studies using cDNA microarrays. Am J Surg Pathol. 2003, 27: 199-205. 10.1097/00000478-200302000-00008.CrossRefPubMed Young AN, Salles PG, Lim SD, et al: Beta defensin-1, parvalbumin, and vimentin: a panel of diagnostic immunohistochemical markers for renal tumors derived from gene expression profiling studies using cDNA microarrays. Am J Surg Pathol. 2003, 27: 199-205. 10.1097/00000478-200302000-00008.CrossRefPubMed
8.
go back to reference Gambichler T, Skrygan M, Huyn J, et al: Pattern of mRNA expression of beta-defensins in basal cell carcinoma. BMC Cancer. 2006, 6: 163-168. 10.1186/1471-2407-6-163.PubMedCentralCrossRefPubMed Gambichler T, Skrygan M, Huyn J, et al: Pattern of mRNA expression of beta-defensins in basal cell carcinoma. BMC Cancer. 2006, 6: 163-168. 10.1186/1471-2407-6-163.PubMedCentralCrossRefPubMed
9.
go back to reference Joly S, Compton LM, Pujol C, Kurago ZB, et al: Loss of human β-definsin 1, 2, and 3 expression in oral squamous cell carcinoma. Oral Micro Immun. 2009, 24: 353-360. 10.1111/j.1399-302X.2009.00512.x.CrossRef Joly S, Compton LM, Pujol C, Kurago ZB, et al: Loss of human β-definsin 1, 2, and 3 expression in oral squamous cell carcinoma. Oral Micro Immun. 2009, 24: 353-360. 10.1111/j.1399-302X.2009.00512.x.CrossRef
10.
go back to reference Schultz AN, Yin-Goen Q, Amin MB: Molecular classification of renal tumors by gene expression profiling. J Mol Diagn. 2005, 7: 206-218. 10.1016/S1525-1578(10)60547-8.CrossRef Schultz AN, Yin-Goen Q, Amin MB: Molecular classification of renal tumors by gene expression profiling. J Mol Diagn. 2005, 7: 206-218. 10.1016/S1525-1578(10)60547-8.CrossRef
11.
go back to reference Arimura Y, Ashitani J, Yanagi S: Elevated serum beta-defensins concentrations in patients with lung cancer. Anticancer Res. 2004, 24: 4051-4057.PubMed Arimura Y, Ashitani J, Yanagi S: Elevated serum beta-defensins concentrations in patients with lung cancer. Anticancer Res. 2004, 24: 4051-4057.PubMed
12.
go back to reference Shnitsar VM, Lisovskiy IL, Soldatkina MA, et al: Human beta-defensin 3 (hBD-3) expression in A431 cell line and human vulval tumors. Exp Oncol. 2004, 26: 328-330.PubMed Shnitsar VM, Lisovskiy IL, Soldatkina MA, et al: Human beta-defensin 3 (hBD-3) expression in A431 cell line and human vulval tumors. Exp Oncol. 2004, 26: 328-330.PubMed
13.
go back to reference Sawaki K, Mizukawa N, Yamaai T, Yoshimoto T, et al: High concentration of beta-defensin 2 in oral squamous cell carcinoma. Anticancer Res. 2002, 22: 2103-2107.PubMed Sawaki K, Mizukawa N, Yamaai T, Yoshimoto T, et al: High concentration of beta-defensin 2 in oral squamous cell carcinoma. Anticancer Res. 2002, 22: 2103-2107.PubMed
14.
go back to reference Bissell J, Joly S, Johnson GK, et al: Expression of β-defensins in gingival health and in periodontal disease. J Oral Pathol Med. 2004, 33: 278-285. 10.1111/j.0904-2512.2004.00143.x.CrossRefPubMed Bissell J, Joly S, Johnson GK, et al: Expression of β-defensins in gingival health and in periodontal disease. J Oral Pathol Med. 2004, 33: 278-285. 10.1111/j.0904-2512.2004.00143.x.CrossRefPubMed
15.
go back to reference Kawar HI, Weinberg A, Hirsh S, et al: Overexpression of human β-Defensin 3 in oral dysplasia: Potential role in macrophage trafficking. Oral Oncol. 2009, 45: 12-19. Kawar HI, Weinberg A, Hirsh S, et al: Overexpression of human β-Defensin 3 in oral dysplasia: Potential role in macrophage trafficking. Oral Oncol. 2009, 45: 12-19.
16.
go back to reference Kleinman HK, Martin GR: Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol. 2005, 15: 378-386. 10.1016/j.semcancer.2005.05.004.CrossRefPubMed Kleinman HK, Martin GR: Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol. 2005, 15: 378-386. 10.1016/j.semcancer.2005.05.004.CrossRefPubMed
17.
go back to reference Quake SR, Scherer A: From micro- to nanofabrication with soft materials in nanotechnology. Science. 2004, 290: 1536-1540.CrossRef Quake SR, Scherer A: From micro- to nanofabrication with soft materials in nanotechnology. Science. 2004, 290: 1536-1540.CrossRef
18.
go back to reference Eicher SA, Clayman GL, Liu TJ, Shillitoe EJ, et al: Evaluation of topical gene therapy for head and neck squamous cell carcinoma in an organotypic model. Clin Cancer Res. 1996, 10: 1659-1664. Eicher SA, Clayman GL, Liu TJ, Shillitoe EJ, et al: Evaluation of topical gene therapy for head and neck squamous cell carcinoma in an organotypic model. Clin Cancer Res. 1996, 10: 1659-1664.
19.
go back to reference Ghosh SK, Gerken TA, Schneider KM, Feng Z, et al: Quantification of human beta-defensin-2 and −3 in body fluids: application for studies of innate immunity. Clin Chem. 2007, 53: 757-765. 10.1373/clinchem.2006.081430.CrossRefPubMed Ghosh SK, Gerken TA, Schneider KM, Feng Z, et al: Quantification of human beta-defensin-2 and −3 in body fluids: application for studies of innate immunity. Clin Chem. 2007, 53: 757-765. 10.1373/clinchem.2006.081430.CrossRefPubMed
20.
go back to reference Amo Y, Masuzawa M, Hamada Y, Katsuoka K: Serum concentrations of vascular endothelial growth factor-D in angiosarcoma patients. Br J Dermatol. 2004, 150: 160-163. 10.1111/j.1365-2133.2004.05751.x.CrossRefPubMed Amo Y, Masuzawa M, Hamada Y, Katsuoka K: Serum concentrations of vascular endothelial growth factor-D in angiosarcoma patients. Br J Dermatol. 2004, 150: 160-163. 10.1111/j.1365-2133.2004.05751.x.CrossRefPubMed
Metadata
Title
Effect of human beta-defensin-3 on head and neck cancer cell migration using micro-fabricated cell islands
Authors
Kevin Wang
Joanne H Wang
Harihara Baskaran
Russell Wang
Rick Jurevic
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Head & Neck Oncology / Issue 1/2012
Electronic ISSN: 1758-3284
DOI
https://doi.org/10.1186/1758-3284-4-41

Other articles of this Issue 1/2012

Head & Neck Oncology 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine